Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [3][47]. Core Views - The pharmaceutical index increased by 3.29% from November 10 to November 14, outperforming the CSI 300 index by 4.37%. The report suggests focusing on core innovative drug assets and companies with clear performance trends [4][17]. - Arrowhead Pharmaceuticals is highlighted for its strong pipeline in RNAi therapies, particularly its TRiM platform, which targets various diseases and has shown significant stock price appreciation [7][8]. - The report emphasizes the ongoing transformation in the Chinese pharmaceutical industry, with a shift towards innovation and international expansion, driven by aging demographics and increasing healthcare demands [35][36]. Summary by Sections Arrowhead Pipeline Progress - Arrowhead Pharmaceuticals has a robust pipeline focusing on targeted siRNA drugs, with significant advancements in cardiovascular and neurological diseases. The stock price has surged by 313% since its lowest point in 2025 [7][8]. - Key products include Plozasiran, which is expected to significantly reduce triglyceride levels and is pending FDA approval [12][13]. Industry Perspective - The report underscores the importance of innovative drugs as a primary investment theme for the year, with a focus on manufacturing, international expansion, and aging consumer demographics [17][35]. - The pharmaceutical index has shown a year-to-date increase of 22.09%, indicating strong market performance [17][24]. Investment Recommendations - Suggested stocks include innovative drug companies such as Xinyi Tai, Sanofi, and China Biopharmaceuticals, as well as companies in the medical device sector like Mindray and United Imaging [39][36]. - The report also highlights the potential for growth in sectors related to aging populations and outpatient consumption, recommending companies like Kunming Pharmaceutical and Yuyue Medical [38][36].

Major Events - Universal Medical (02666) plans to invest 15.03 million yuan to establish a joint venture that will create a collaborative platform integrating policy alignment, technology transfer, and clinical validation [1] - Fosun Pharma (02196) subsidiary has had its drug registration application for polyethylene glycol electrolyte solution accepted by the National Medical Products Administration [1] - China Biologic Products (01177) received approval from NMPA for the clinical trial application of LM-350 "CDH17 ADC" [1] - Xianruida Medical-B (06669) has received approval from the National Medical Products Administration for the registration of its coronary overall exchange balloon dilation catheter [1] - Meili Tianyuan Medical Health (02373) subsidiary plans to acquire medical and beauty assets related to Nairuier for 40 million yuan, adding 19 direct-operated stores [1] - China Tongru (01763) has exported its self-produced irradiation equipment to the Latin American market for the first time [1] Operating Performance - Trip.com Group-S (09961) reported a third-quarter net profit of 19.89 billion yuan, an increase of 194.01% year-on-year [1] - H&H International Holdings (01112) reported a 12.0% year-on-year increase in total revenue for the first three quarters [1] - Weibo-SW (09898) reported a net profit attributable to shareholders of 454 million USD for the third quarter, an increase of 55.43% year-on-year [1] - Baidu Group-SW (09888) reported total revenue of 31.2 billion yuan in the third quarter, with AI new business revenue growing over 50% year-on-year [1] - Xiaomi Group-W (01810) achieved a record adjusted net profit of 11.31 billion yuan in the third quarter, with smartphone shipments increasing year-on-year for nine consecutive quarters [1] - China Oriental Group (00581) reported sales of approximately 2.1 million tons of self-produced steel products in the third quarter [1] - BOSS Zhipin-W (02076) reported an adjusted net profit of approximately 999.2 million yuan in the third quarter, an increase of 34.2% year-on-year [1]

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Lixin Pharmaceutical Technology, has received clinical trial approval from the NMPA for its innovative drug LM-350, a CDH17-targeted antibody-drug conjugate (ADC) [1][2] Group 1: Product Development - LM-350 is developed based on Lixin's next-generation LM-ADC™ platform and selectively binds to CDH17, demonstrating strong internalization capabilities [1] - The drug utilizes an IgG1 wild-type configuration and exhibits antibody-dependent cellular cytotoxicity (ADCC) activity [1] - Preclinical studies show significant anti-tumor activity of LM-350 in various xenograft models, particularly in colorectal cancer models resistant to MMAE or irinotecan [1] Group 2: Market Potential - CDH17 is highly expressed in various cancers, including approximately 99% in colorectal cancer, 86% in gastric adenocarcinoma, 79% in esophageal adenocarcinoma, and 50% in pancreatic ductal adenocarcinoma [1] - Gastrointestinal cancers, including colorectal, gastric, pancreatic, and esophageal cancers, represent one of the highest incidence and mortality rates globally, with over 4 million new cases reported in 2022, indicating a significant unmet clinical need [1] Group 3: Regulatory Progress - LM-350 has previously received IND approval from the FDA, with the first patient enrollment in Australia expected by September 2025 [2] - The approval of the clinical trial application in China will accelerate the clinical research process, aiming to provide new treatment options for patients sooner [2]

格隆汇11月18日丨中国生物制药(01177.HK)宣布，集团全资附属公司礼新医药科技(上海)有限公司("礼 新医药")自主研发的国家1类创新药LM-350"CDH17抗体偶联药物(ADC)"已获得中国国家药品监督管理 局(NMPA)的临床试验批准。 根据披露，LM-350是基于礼新医药新一代LM-ADC?平台开发的一款靶向CDH17的ADC，能够高度选择 性地结合CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导的 细胞毒性作用(ADCC)活性。临床前研究显示，LM-350在多个异种移植模型中表现出显著的抗肿瘤活 性，尤其在对MMAE耐药或伊立替康耐药的结直肠癌移植瘤模型中效果突出。 ...

中国生物制药(01177)发布公告，集团全资附属公司礼新医药科技(上海)有限公司(礼新医药)自主研发的 国家1类创新药LM-350"CDH17抗体偶联药物(ADC)"已获得中国国家药品监督管理局(NMPA)的临床试 验批准。 CDH17在多种肿瘤侵袭转移中发挥重要作用，并在约99%的结肠癌、86%的胃腺癌、79%的食管腺癌、 50%的胰腺导管腺癌中高表达。消化道肿瘤(包括结直肠癌、胃癌、胰腺癌、食管癌等)是全球发病率和 死亡率最高的癌症种类之一，2022年全球新发患者数量超过400万人，存在巨大的尚未被满足的临床需 求。 此前，LM-350已获得美国食品药品监督管理局(FDA)的IND批件，并于2025年9月在澳大利亚完成首例 患者入组。随着此次中国临床试验申请的获批，礼新医药将加速推进中国临床研究，致力于尽早为患者 提供全新的治疗选择。 LM-350是基于礼新医药新一代LM-ADC平台开发的一款靶向CDH17的ADC，能够高度选择性地结合 CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导的细胞毒性 作用(ADCC)活性。临床前研究显示，LM-350在多个异种移植模 ...

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a downturn, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 2% and falling below the 10-day moving average, indicating potential buying opportunities for investors [1][3]. Group 1: Market Performance - Major stocks in the innovative drug sector, such as Kangfang Biotech, fell by 4.5%, while others like 3SBio, China Biologic Products, and CSPC Pharmaceutical also declined [3]. - BeiGene's stock initially rose by 5.5% but later retreated along with the broader market [3]. - The innovative drug index has corrected approximately 20% from its peak, with some companies experiencing declines of 30% to 50%, shifting market sentiment from overly optimistic to a more pessimistic outlook [4]. Group 2: Investment Opportunities - Despite recent downturns, there is a rationale for renewed optimism in the innovative drug sector, as Chinese companies are reshaping the global innovative drug research ecosystem [4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is highlighted as a preferred investment tool, with its index comprising purely innovative drug companies and a significant concentration in leading firms [4]. - The top ten stocks in the ETF account for over 71% of its weight, showcasing the dominance of leading companies in the sector [5]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) has a total market value of 2.12 billion HKD and an average daily trading volume of 466 million HKD since its inception, making it the largest and most liquid ETF tracking the same index [5]. - The ETF's index, the Hang Seng Stock Connect Innovative Drug Select Index, is designed to exclude CXO companies, focusing solely on innovative drug development firms [4].

港股全天震荡走低，三大指数盘中均跌超1%。截止收盘，恒生指数跌0.71%或188.18点，报26384.28 点，全日成交额为2176.13亿港元；恒生国企指数跌0.74%，报9328.4点；恒生科技指数跌0.96%，报 5756.88点。 银河证券表示，展望未来，市场风险偏好趋于谨慎，场内热点轮动加快，港股或延续震荡走势。建议关 注以下板块："反内卷"政策效果逐渐显现，供需格局变化下，商品价格上涨的周期股或持续反弹；美联 储降息政策面临较大不确定性，市场风险偏好下降，投资者或转向红利股寻求防御。 蓝筹股表现 携程集团-S(09961)全天承压。截至收盘，跌3.56%，报555.5港元，成交额17.59亿港元，拖累恒指8.8 点。11月14日，外交部和中国驻日本使领馆郑重提醒中国公民近期避免前往日本。11月16日，红星新闻 致电携程，客服表示平台方也在密切关注。现在有很多日本的酒店订单取消，在帮顾客处理；有的客人 还在观望。部分酒店好沟通，同意免费退改，携程可直接提交申请并自动退款；部分酒店则需进一步沟 通，尚在协调中。 其他蓝筹股方面，康师傅控股(00322)涨2.08%，报12.25港元，贡献恒指0.77 ...

智通财经APP获悉，港股全天震荡走低，三大指数盘中均跌超1%。截止收盘，恒生指数跌0.71%或 188.18点，报26384.28点，全日成交额为2176.13亿港元；恒生国企指数跌0.74%，报9328.4点；恒生科 技指数跌0.96%，报5756.88点。 银河证券表示，展望未来，市场风险偏好趋于谨慎，场内热点轮动加快，港股或延续震荡走势。建议关 注以下板块："反内卷"政策效果逐渐显现，供需格局变化下，商品价格上涨的周期股或持续反弹；美联 储降息政策面临较大不确定性，市场风险偏好下降，投资者或转向红利股寻求防御。 蓝筹股表现 携程集团-S(09961)全天承压。截至收盘，跌3.56%，报555.5港元，成交额17.59亿港元，拖累恒指8.8 点。11月14日，外交部和中国驻日本使领馆郑重提醒中国公民近期避免前往日本。11月16日，红星新闻 致电携程，客服表示平台方也在密切关注。现在有很多日本的酒店订单取消，在帮顾客处理；有的客人 还在观望。部分酒店好沟通，同意免费退改，携程可直接提交申请并自动退款；部分酒店则需进一步沟 通，尚在协调中。 其他蓝筹股方面，康师傅控股(00322)涨2.08%，报12.25港 ...

Group 1 - The core viewpoint is that the Hong Kong innovative drug concept stocks are experiencing a continuous decline, with Federal Pharmaceutical dropping over 8% [1] - Other companies such as Crystal Technology Holdings, Giant Biologics, Sanofi Pharmaceutical, and China Biopharmaceutical are also following the downward trend [1]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - The acquisition of Crown Bioscience International by the report's subject company,艾迪康, for a base consideration of $204 million (approximately 1.48 billion RMB), marks a strategic shift from clinical testing services to drug development, aligning with the trend of collaborative development in precision medicine [3][13] - The report emphasizes the importance of CROs possessing translational medicine capabilities to facilitate the rapid transition from preclinical biomarkers to clinical trials and diagnostic processes [3] Summary by Sections Industry Overview -艾迪康 announced the acquisition of Crown Bioscience International, a global CRO focused on oncology and immuno-oncology drug discovery and development, with the transaction expected to complete by mid-2026 [3] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as 恒瑞医药, 百济神州, and 中国生物制药, as well as companies with significant single-product potential like 一品红 and 三生制药 [5] - It also highlights the importance of companies with leading positions in cutting-edge technology platforms, such as 东诚药业 and 远大医药, and suggests monitoring the CXO sector for stable growth in R&D investment [5] Market Performance - The pharmaceutical sector saw a 3.29% increase last week, ranking 4th among 28 industries, while the Hong Kong pharmaceutical sector rose by 6.80%, ranking 2nd among 11 industries [7][30] - The report notes that the valuation of the pharmaceutical sector is currently at 30.89 times (TTM), with a premium of 22.29% over the overall A-shares [23]